Reviewing Inovio Pharmaceuticals (NASDAQ:INO) and Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Lexicon Pharmaceuticals and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-161.80%	-35.76%	-24.53%
Inovio Pharmaceuticals	N/A	-383.92%	-76.43%

Institutional & Insider Ownership

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Inovio Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$38.54 million	21.32	-$50.34 million	($0.14)	-13.18
Inovio Pharmaceuticals	$60,000.00	2,671.86	-$84.95 million	($0.91)	-1.60

Lexicon Pharmaceuticals has higher revenue and earnings than Inovio Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lexicon Pharmaceuticals has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lexicon Pharmaceuticals and Inovio Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1	1	3	0	2.40
Inovio Pharmaceuticals	1	1	5	0	2.57

Lexicon Pharmaceuticals presently has a consensus price target of $5.80, indicating a potential upside of 214.36%. Inovio Pharmaceuticals has a consensus price target of $6.33, indicating a potential upside of 335.28%. Given Inovio Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.